Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07346287 · ClinicalTrials.gov registry record · Phase 4
ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
A Phase 4 study of Vaginal Atrophy and Atrophic Vaginitis, sponsored by Stratpharma.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07346287: Recruiting Phase 4 study of Vaginal Atrophy and Atrophic Vaginitis, sponsored by Stratpharma.
NCT07346287 is a Phase 4 study of Vaginal Atrophy and Atrophic Vaginitis that is actively recruiting participants, run by Stratpharma. The registered enrollment target is 10 participants, below the 355-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07346287, a Phase 4 study of Vaginal Atrophy and Atrophic Vaginitis, is actively recruiting participants, sponsored by Stratpharma.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment. Clinical outcomes will be assessed using validated investigator- and patient-reported measures, with safety and symptom progression monitored throughout the study.
Primary Outcome
Objective clinical assessment for assessment of the device safety as adjunctive treatment after laser therapy forr women with vaginal atrophy. The objective validation of clinical signs (elasticity, fluid volume, pH, epithelial integrity, moisture) using a commonly used scale.
Conditions Studied
Interventions
- DEVICE 7-940
Study Locations (1)
California
- Orange Coast Women's Medical Group - Laguna Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-08-13 |
| Est. Completion | 2026-04 |
| Phase | Phase 4 |
What NCT07346287 shows while recruiting
NCT07346287 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 355-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Vaginal Atrophy appearing as the primary indexed condition, and to 1 intervention - of which 7-940 is the first listed.
NCT07346287 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07346287 about?
NCT07346287 is a clinical study titled "ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy". Vaginal atrophy patients receiving vaginal laser therapy will be treated with daily 7-0940® following a laser session to evaluate the safety and efficacy of the product as an adjunct treatment. Clinical outcomes will be assessed using validated investigator- and patient-reported measures, with safet...
What is the current status of trial NCT07346287?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2025-08-13. Estimated completion is 2026-04.
What conditions does trial NCT07346287 study?
This clinical trial studies the following conditions: Vaginal Atrophy, Atrophic Vaginitis, Genitourinary Syndrome of Menopause (GSM).
What interventions are being tested in trial NCT07346287?
The interventions under investigation include: 7-940 (DEVICE).
Who is sponsoring clinical trial NCT07346287?
This trial is sponsored by Stratpharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07346287 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaginal Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07346287's enrollment target sits among peer trials
10 10th of 9 the lowest of 9 other Vaginal Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vaginal Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo
RECRUITING · Phase 4
-
Postpartum Vaginal Estrogen for Breastfeeding Patients
RECRUITING · Phase 4
-
Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy
COMPLETED · Phase 4
-
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
RECRUITING · NA
-
PRP Injections for Genitourinary Syndrome of Menopause
ACTIVE NOT RECRUITING · NA
-
Topical DHEA Against Vaginal Atrophy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI